Oscar Health, Inc. (OSCR) experienced a significant surge in its stock price, soaring 5.05% in trading on Wednesday. This impressive rally comes on the heels of the company's release of its exceptional first-quarter financial results for 2025, which substantially exceeded analyst expectations across key metrics.
The health insurance technology firm reported a remarkable first-quarter earnings per share (EPS) of $0.92, handily beating the consensus estimate range of $0.79-$0.83. Oscar Health's revenue for the quarter reached $3.05 billion, representing a substantial 42% year-over-year increase and surpassing the expected $2.86-$2.87 billion. This strong top-line growth was primarily attributed to higher membership numbers. Furthermore, the company demonstrated improved operational efficiency with an adjusted EBITDA of $328.8 million, significantly outperforming the analyst estimate of $280.8 million.
Oscar Health's ability to translate growth into profitability was evident in its impressive net income of $275.3 million. The company's medical loss ratio stood at 75.4%, while the SG&A expense ratio improved to 15.8%, down from 18.4% in the same quarter last year, indicating enhanced cost management. Adding to investor optimism, Oscar Health reaffirmed its full-year 2025 guidance across all metrics, further solidifying confidence in the company's future prospects within the evolving healthcare technology landscape.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。